About Stacey Seltzer:Ms. Seltzer joined Aisling in 2008 and serves as a Partner. Prior to Aisling, Ms. Seltzer was at Schering-Plough, where she held roles in business development, marketing and sales, most recently serving at U.S. Schering-Plough as Brand Lead for Zetia. While in business development, Ms. Seltzer was involved in the structuring and negotiation of several deals with an aggregate value in the billions, ranging from in-licensing deals to broad development and commercialization alliances. Prior to Schering-Plough, Ms. Seltzer was the Director of Business Development for Akceli, a biotechnology company developing cell-based microarrays. Ms. Seltzer began her career as a management consultant for McKinsey & Company.

Ms. Seltzer currently serves as a director of Aimmune Therapeutics and Promentis Pharmaceuticals, and as a board observer of Prolacta Bioscience. Her prior board service includes Agile Therapeutics, AVROBIO, Durata Therapeutics (acquired by Actavis), Miramar Labs (acquired by Sientra) and ZELTIQ Aesthetics (acquired by Allergan). She also acted as the Aisling representative for its investment in PreCision Dermatology (acquired by Valeant). Ms. Seltzer serves on the Life Science Council for Springboard Enterprises and the Investment Advisory Board of the Blavatnik Fund for Innovation at Yale.

About the Blavatnik Fund for Innovation at Yale

The Blavatnik Fund for Innovation at Yale bridges the gap between innovative, early-stage life science research and successful development of high-impact biomedical products. Our integrated approach combines essential funding with development and business expertise, leading to commercial partnerships that bring forth new biomedical discoveries that create value and benefit society.